Last reviewed · How we verify
IBI311
IBI311, a small molecule developed by Shanghai Changzheng Hospital, is currently marketed but lacks specified primary indications and revenue data. The drug's key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. Without detailed trial results or identified competitors, the primary risk remains uncertain, but the patent expiry poses a significant long-term threat.
At a glance
| Generic name | IBI311 |
|---|---|
| Sponsor | Shanghai Changzheng Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy (PHASE3)
- Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (EARLY_PHASE1)
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease (PHASE3)
- A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease (PHASE2)
- Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO (PHASE4)
- The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment. (PHASE4)
- Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment. (PHASE4)
- A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |